Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity

US6790846B2 · kind B2 · utility

Assignee

• The Procter & Gamble Company · US

Inventors

• Michael P. Clark · Maineville, US
• Jane Far-Jine Djung · Mason, US
• Steven Karl Laughlin · Independence, US
• Joshua Spector Tullis · Broomfield, US
• Michael G. Natchus · Alpharetta, US
• Biswanath De · Mason, US

Key dates

• Filing date: May 7, 2002
• Grant date: Sep 14, 2004
• Expiry date: Sep 28, 2022

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Isoxazolone compounds having the generic structure: are used to treat disease associated with unwanted cytokine activity, including rheumatoid arthritis, osteoarthritis, diabetes, HIV/AIDS, inflammatory bowel disease, Crohn's disease, ulcerative colitis, congestive heart, hypertension, chronic obstructive pulmonary disease, septic shock syndrome, tuberculosis, adult respiratory distress, asthma, atherosclerosis, muscle degeneration, periodontal disease, cachexia, Reiter's syndrome, gout, acute synovitis, anorexia and bulimia nervosa fever, malaise, myalgia and headaches.